The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield™ as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
Sendai virus enables delivery of genes into a host cell without permanently altering the cell’s chromosome, which is critical for stem cell therapies. Professor Shinya Yamanaka, MD, Ph.D.,
The two-year project, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), will allow Symic to perform additional preclinical efficacy studies and advance lead
Immatics believes that ACT approaches to be developed by the new company can achieve a step change in the treatment of cancer, by delivering significant, long-lasting clinical benefits.
The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen’s University in Kingston, Ontario . "Non-small cell lung cancer continues to
The AMBITION study was a randomised, double-blind Phase 3b/4 study designed to compare the efficacy and safety of ambrisentan in combination with tadalafil to monotherapy in treatment-naïve patients
Pursuant to the study agreement, UMass Medical School will provide Enumeral with tissue samples and blood samples from subjects with melanoma who are being treated with Ipilimumab (Yervoy).
The product, which is based on Corium’s proprietary transdermal formulation and adhesive technology, is designed to deliver donepezil (the active ingredient in Aricept) for up to seven days
Afatinib has also been granted orphan drug designation by the FDA – a status given to a product intended for the treatment of a rare disease or condition.
As previously announced, the investigational drug was granted FDA Fast Track designation for the treatment of recurrent high-grade glioma, which includes glioblastoma and anaplastic astrocytoma, and is poised
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.